hepatitis%20c
HEPATITIS C

Hepatitis C can be transmitted through blood transfusions, organ transplants, percutaneous (especially IV drug use), sexual or perinatal route.

It has an incubation period of 14-180 days.

Goal of treatment is to prevent progression to chronic hepatitis C through antiviral treatment of acute hepatitis C. Also, it aims to prevent occurrence of liver-related complications through antiviral treatment of chronic hepatitis C.

Hepatitis%20c Patient Education

Patient Education

Partner Notification

  • Partner notification for at-risk contacts
    • Contact tracing to include any sexual contact (penetrative vaginal or anal sex) or needle-sharing partners from 2 weeks before the onset of jaundice
    • If without acute infection, trace back to the likely time of infection eg blood transfusion, 1st needle sharing

Patient Education

  • Provide the patients with a detailed explanation of their condition
    • Emphasize the disease’s long-term implications (eg long-term medical therapy, continuous monitoring for liver disease progression) for their and their partners’ health
    • Counsel regarding the importance of treatment adherence, proper dosing administration, and reporting of medication changes 
    • Provide clear, accurate, written information
  • Advise patient not to donate blood, semen or organs
  • Advise patient to avoid sharing items of personal hygiene eg toothbrushes, shaving equipment
  • Counsel patient to stop using illicit drugs
  • Advise patient regarding sexual transmission
    • HCV is not considered to be a sexually transmitted disease, but sexual promiscuity, HIV and herpes simplex virus (HSV-2) coinfections are associated with sexual transmission of hepatitis C
    • Avoid unprotected sex during menstruation
  • Advise patient regarding the potential deleterious effect of alcohol especially in association with development of HCC, progression of liver fibrosis and increase in HCV replication
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Updates from the SECURE-IBD* registry reveal that treatment with thiopurine, either alone or in combination with tumour necrosis factor inhibitors (TNFis), for inflammatory bowel disease (IBD) was associated with a greater risk of severe COVID-19 compared with TNFis monotherapy.